The involvement of norepinephrine, neuropeptide Y, and nitric oxide in the cutaneous vasodilator response to local heating in humans

J Appl Physiol (1985). 2008 Jul;105(1):233-40. doi: 10.1152/japplphysiol.90412.2008. Epub 2008 May 15.

Abstract

Presynaptic blockade of cutaneous vasoconstrictor nerves (VCN) abolishes the axon reflex (AR) during slow local heating (SLH) and reduces the vasodilator response. In a two-part study, forearm sites were instrumented with microdialysis fibers, local heaters, and laser-Doppler flow probes. Sites were locally heated from 33 to 40 degrees C over 70 min. In part 1, we tested whether this effect of VCN acted via nitric oxide synthase (NOS). In five subjects, treatments were as follows: 1) untreated; 2) bretylium, preventing neurotransmitter release; 3) N(G)-nitro-L-arginine methyl ester (L-NAME) to inhibit NOS; and 4) combined bretylium + L-NAME. At treated sites, the AR was absent, and there was an attenuation of the ultimate vasodilation (P < 0.05), which was not different among those sites (P > 0.05). In part 2, we tested whether norepinephrine and/or neuropeptide Y is involved in the cutaneous vasodilator response to SLH. In seven subjects, treatments were as follows: 1) untreated; 2) propranolol and yohimbine to antagonize alpha- and beta-receptors; 3) BIBP-3226 to antagonize Y(1) receptors; and 4) combined propranolol + yohimbine + BIBP-3226. Treatment with propranolol + yohimbine or BIBP-3226 significantly increased the temperature at which AR occurred (n = 4) or abolished it (n = 3). The combination treatment consistently eliminated it. Importantly, ultimate vasodilation with SLH at the treated sites was significantly (P < 0.05) less than at the control. These data suggest that norepinephrine and neuropeptide Y are important in the initiation of the AR and for achieving a complete vasodilator response. Since VCN and NOS blockade in combination do not have an inhibition greater than either alone, these data suggest that VCN promote heat-induced vasodilation via a nitric oxide-dependent mechanism.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adrenergic Antagonists / pharmacology
  • Adrenergic alpha-Antagonists / pharmacology
  • Adrenergic beta-Antagonists / pharmacology
  • Adult
  • Arginine / analogs & derivatives
  • Arginine / pharmacology
  • Axons / drug effects
  • Axons / physiology
  • Enzyme Inhibitors / pharmacology
  • Female
  • Hot Temperature*
  • Humans
  • Male
  • Microdialysis
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Neuropeptide Y / antagonists & inhibitors
  • Neuropeptide Y / physiology*
  • Nitric Oxide / antagonists & inhibitors
  • Nitric Oxide / biosynthesis
  • Nitric Oxide / physiology*
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Norepinephrine / antagonists & inhibitors
  • Norepinephrine / physiology*
  • Propranolol / pharmacology
  • Receptors, Neuropeptide Y / antagonists & inhibitors
  • Receptors, Presynaptic / drug effects
  • Reflex / drug effects
  • Reflex / physiology
  • Regional Blood Flow / drug effects
  • Regional Blood Flow / physiology
  • Skin / blood supply*
  • Vasodilation / drug effects
  • Vasodilation / physiology*
  • Yohimbine / pharmacology

Substances

  • Adrenergic Antagonists
  • Adrenergic alpha-Antagonists
  • Adrenergic beta-Antagonists
  • BIBP 3226
  • Enzyme Inhibitors
  • Neuropeptide Y
  • Receptors, Neuropeptide Y
  • Receptors, Presynaptic
  • Yohimbine
  • Nitric Oxide
  • Arginine
  • Propranolol
  • Nitric Oxide Synthase
  • NG-Nitroarginine Methyl Ester
  • Norepinephrine